🇺🇸 FDA
Patent

US 11464774

Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors

granted A61KA61K31/282A61K31/4965

Quick answer

US patent 11464774 (Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors) held by Vertex Pharmaceuticals Incorporated expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/282, A61K31/4965, A61K31/497, A61K31/519